A meta-analysis showed that patients with type 2 diabetes mellitus (T2DM) treated with one of the subtype selective SGLT2 inhibitors (gliflozin) exhibited significant protection in terms of cerebrovascular and cardiovascular outcomes and mortality compared to T2DM patients treated with other agents [14]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.